Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP1LC3B | Q9GZQ8 | 7/20 | 0.52 |
| ▸ | CRBN | Q96SW2 | 10/20 | 0.51 |
| ▸ | STAT3 | P40763 | 1/20 | 0.51 |
| ▸ | GSPT1 | P15170 | 2/20 | 0.49 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.49 |
| ▸ | SALL4 | Q9UJQ4 | 2/20 | 0.49 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.49 |
| ▸ | BRD4 | O60885 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25031848 | 1.00 | MAP1LC3B (0.52) | MAP1LC3BCRBNSTAT3GSPT1CSNK1A1 | |
| SCHEMBL25756266 | 0.96 | MAP1LC3B (0.49) | MAP1LC3BCRBNSTAT3GSPT1CSNK1A1 | |
| SCHEMBL25756263 | 0.95 | MAP1LC3B (0.48) | MAP1LC3BCRBNSTAT3GSPT1CSNK1A1 | |
| SCHEMBL25032246 | 0.95 | MAP1LC3B (0.48) | MAP1LC3BCRBNSTAT3GSPT1CSNK1A1 | |
| SCHEMBL23772825 | 0.94 | MAP1LC3B (0.51) | MAP1LC3BCRBNSTAT3IKZF3BRD4 | |
| SCHEMBL23772439 | 0.94 | MAP1LC3B (0.51) | MAP1LC3BCRBNSTAT3IKZF3BRD4 | |
| SCHEMBL23772670 | 0.94 | MAP1LC3B (0.51) | MAP1LC3BCRBNSTAT3IKZF3BRD4 | |
| SCHEMBL23037219 | 0.92 | CRBN (0.52) | MAP1LC3BCRBNIKZF3BRD4 | |
| SCHEMBL30891811 | 0.92 | STAT3 (0.53) | MAP1LC3BCRBNSTAT3BRD4 | |
| SCHEMBL30891789 | 0.92 | STAT3 (0.53) | MAP1LC3BCRBNSTAT3BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | MAP1LC3B 720/4885CRBN 286/4885STAT3 3869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.